Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the acquisition and launch of acetylcysteine injection, 6 gm/30 mL (200 mg/mL) single-dose vials. Glenmark’s acetylcysteine injection, 6 gm/30 ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial. Glenmark's Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) ...

3 A total of 839 patients were randomly assigned to receive either nivolumab as monotherapy at a dose of 240 mg once every 2 weeks for 6 doses, followed by nivolumab 480 mg once every 4 weeks (Q4W), ...

A total of 709 patients were enrolled in CheckMate 274, including 353 patients (of whom 140 patients had PD-L1 ≥ 1%) who were randomly assigned to take nivolumab 240 mg every 2 weeks ...

Patients were randomly assigned 1:1 to either nivolumab 240 mg intravenously once every 2 weeks and cabozantinib 40 mg once per day by mouth or sunitinib 50 mg once per day by mouth on a cycle of 4 ...

SEOUL, South Korea, Feb. 18, 2025 /PRNewswire/ -- On February 17, VIVOZON Pharmaceutical announced that its non-opioid analgesic, UNAFRA Inj., was approved on December 12, 2024. (active ingredient: ...

Evaluating the efficacy of cabozantinib in patients with advanced renal cell carcinoma with bone metastasis: An open-label phase 2 study. This is an ASCO Meeting Abstract from the 2025 ASCO ...

The pathology results confirmed melanoma with lymph node metastases. BRAF mutation was negative. He was put on adjuvant nivolumab (240 mg every 2 weeks) for 1 month after the operation. After 16 ...

SD ICI was defined as the FDA-approved dose of pembrolizumab 200 mg every 3 weeks or 400 mg every 6 weeks, nivolumab 240 mg every 2 weeks, or 480 mg 4 weeks, atezolizumab 1200 mg every 3 weeks, and ...